Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for pain in knee osteoarthritis with delayed TKR
NCT04386980Phase 3Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
A Phase 3 trial of resiniferatoxin in osteoarthritis (OA), sponsored by Sorrento Therapeutics. Planned start Apr 2021; status: withdrawn.
02
Drugs
resiniferatoxin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04386980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386980.